Clinical evaluation of INNO-LiPA HPV Genotyping EXTRA II assay using the VALGENT framework
ID Xu, Lan (Author), ID Padalko, Elizaveta (Author), ID Oštrbenk Valenčak, Anja (Author), ID Poljak, Mario (Author), ID Arbyn, Marc (Author)

.pdfPDF - Presentation file, Download (238,72 KB)
MD5: EF91254A13739BD8F09FAACBB73D7247
URLURL - Source URL, Visit https://www.mdpi.com/1422-0067/19/9/2704 This link opens in a new window

In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping Extra II (INNO-LiPA) within the VALGENT-3 framework. VALGENT is designed to assess the analytical and clinical performance of HPV tests with genotyping capacity. The VALGENT-3 panel comprised 1300 consecutive cervical cell specimens enriched with 300 samples with abnormal cytology obtained from women attending the Slovenian cervical cancer screening programme. The INNO-LiPA allows type-specific detection of 32 HPV types; however, for the clinical accuracy assessment, we considered it as high-risk (hr)HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and HPV68. Clinical accuracy for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was compared between INNO-LiPA and Hybrid Capture 2 (HC2), which is a standard comparator test for HPV tests used in cervical cancer screening. In addition, hrHPV and type-specific detection HPV types were compared between INNO-LiPA and Linear Array HPV Genotyping Test (Linear Array). The prevalence of hrHPV determined by INNO-LiPA was 17.1% (95% CI, 15.0–19.2%) in the screening population. HrHPV testing with INNO-LiPA had a sensitivity for CIN2+ of 96.9% (95% CI, 92.1–99.1%) which was non-inferior to HC2 (relative sensitivity of 1.01; 95% CI, 0.97–1.04; p$_{n.inf}$ = 0.0002) and a specificity for ≤CIN1 of 85.3% (95% CI, 83.2–87.3%) which was inferior to HC2 (relative specificity of 0.95; 95% CI, 0.93–0.97; p$_{n.inf}$ = 0.9998). Genotyping agreement between INNO-LiPA and Linear Array was excellent for hrHPV, HPV16, HPV18, HPV35, HPV45, HPV58 and HPV59, but good or fair for other HPV types. To conclude, INNO-LiPA demonstrated non-inferior clinical sensitivity but lower specificity compared to HC2 in addition to excellent concordance compared to Linear Array for hrHPV and some genotypes.

Keywords:INNO-LiPA, VALGENT, HPV genotyping, cervical cancer, human papillomavirus, clinical validation, Hybrid Capture 2, Linear Array, HPV, INNO - LiPA HPV genotyping EXTRA II
Work type:Article (dk_c)
Organization:MF - Faculty of Medicine
Publication status in journal:Published
Article version:Publisher's version of article
Number of pages:11 str.
Numbering:Vol. 19, iss. 9, art. 2704
ISSN on article:1422-0067
DOI:10.3390/ijms19092704 This link opens in a new window
Publication date in RUL:30.09.2021
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a journal

Title:International journal of molecular sciences
Shortened title:Int. j. mol. sci.
COBISS.SI-ID:2779162 This link opens in a new window


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:11.09.2018

Secondary language


Document is financed by a project

Funder:EC - European Commission
Funding programme:FP7
Project number:603019
Name:Comparing health services interventions for the prevention of HPV-related cancer

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections: